BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics

BioCryst Pharmaceuticals, Inc. (BCRX): $10.58

-0.20 (-1.86%)

POWR Rating

Component Grades













Add BCRX to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where BCRX ranks best; there it ranks ahead of 77.66% of US stocks.
  • BCRX's strongest trending metric is Value; it's been moving up over the last 177 days.
  • BCRX ranks lowest in Stability; there it ranks in the 3rd percentile.

BCRX Stock Summary

  • BIOCRYST PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.08% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -3.01 for BIOCRYST PHARMACEUTICALS INC; that's greater than it is for merely 4.11% of US stocks.
  • As for revenue growth, note that BCRX's revenue has grown 109.11% over the past 12 months; that beats the revenue growth of 92.41% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BIOCRYST PHARMACEUTICALS INC are FRSX, VERU, VLN, TGTX, and BCDA.
  • BCRX's SEC filings can be seen here. And to visit BIOCRYST PHARMACEUTICALS INC's official web site, go to

BCRX Valuation Summary

  • In comparison to the median Healthcare stock, BCRX's EV/EBIT ratio is 351.52% lower, now standing at -24.9.
  • Over the past 243 months, BCRX's price/sales ratio has gone up 0.6.

Below are key valuation metrics over time for BCRX.

Stock Date P/S P/B P/E EV/EBIT
BCRX 2023-01-20 8.1 -8.0 -10.0 -24.9
BCRX 2023-01-19 7.8 -7.7 -9.7 -24.1
BCRX 2023-01-18 7.9 -7.8 -9.7 -24.3
BCRX 2023-01-17 7.8 -7.7 -9.6 -24.1
BCRX 2023-01-13 7.9 -7.8 -9.8 -24.4
BCRX 2023-01-12 8.1 -7.9 -10.0 -24.7

BCRX Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -148.1%.
  • The 2 year net income to common stockholders growth rate now stands at -68.03%.
  • Its 3 year net cashflow from operations growth rate is now at -59.09%.
Over the past 33 months, BCRX's revenue has gone up $189,605,000.

The table below shows BCRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 238.44 -170.46 -193.354
2022-06-30 203.607 -161.292 -209.635
2022-03-31 188.034 -158.946 -193.974
2021-12-31 157.17 -142.157 -184.062
2021-09-30 114.028 -154.337 -226.776
2021-06-30 79.136 -169.316 -214.09

BCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BCRX has a Quality Grade of C, ranking ahead of 64.73% of graded US stocks.
  • BCRX's asset turnover comes in at 0.295 -- ranking 153rd of 682 Pharmaceutical Products stocks.
  • BLCM, VIRX, and GLYC are the stocks whose asset turnover ratios are most correlated with BCRX.

The table below shows BCRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.295 0.901 -0.933
2021-03-31 0.127 0.766 -1.361
2020-12-31 0.083 0.906 -2.051
2020-09-30 0.305 0.922 -3.095
2020-06-30 0.319 0.946 -2.677
2020-03-31 0.368 0.944 -1.858

BCRX Price Target

For more insight on analysts targets of BCRX, see our BCRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.27 Average Broker Recommendation 1.58 (Moderate Buy)

BCRX Stock Price Chart Interactive Chart >

Price chart for BCRX

BCRX Price/Volume Stats

Current price $10.58 52-week high $19.99
Prev. close $10.78 52-week low $7.61
Day low $10.56 Volume 1,780,500
Day high $10.98 Avg. volume 3,267,183
50-day MA $11.32 Dividend yield N/A
200-day MA $11.68 Market Cap 1.97B

BioCryst Pharmaceuticals, Inc. (BCRX) Company Bio

Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina.

BCRX Latest News Stream

Event/Time News Detail
Loading, please wait...

BCRX Latest Social Stream

Loading social stream, please wait...

View Full BCRX Social Stream

Latest BCRX News From Around the Web

Below are the latest news stories about BIOCRYST PHARMACEUTICALS INC that investors may wish to consider to help them evaluate BCRX as an investment opportunity.

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO ® (berotralstat) in Central and Eastern Europe (CEE).

GlobeNewswire | January 23, 2023

BioCryst teams up with Swixx to sell Orladeyo in Central, Eastern Europe

BioCryst Pharmaceuticals (BCRX) is collaborating with Swixx BioPharma to commercialize hereditary angioedema attack (HAE) prevention therapy Orladeyo (berotralstat) in Central and…

Seeking Alpha | January 23, 2023

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO (berotralstat) in Central and Eastern Europe

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO (berotralstat) in Central and Eastern Europe (CEE). “We continue to build partnerships with companies that have deep expertise in commercializing rare disease therapies

Wallstreet:Online | January 23, 2023

T-cell Lymphoma Market Is Booming Worldwide 2023-2030 | F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company

Edition: 2023 The Global T-cell Lymphoma Market Report provides In-depth analysis on the market status of the T-cell Lymphoma Top manufacturers with best facts and figures, meaning, Definition, SWOT and PESTEL analysis, expert opinions and the latest developments across the globe.

OpenPR | January 20, 2023

Results from BioCryst Pharmaceuticals Inc. (BCRX) show potential

The share price of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) rose to $10.11 per share on Wednesday from $10.00. While BioCryst Pharmaceuticals Inc. has overperformed by 1.10%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BCRX fell by -34.69%, with highs and lows ranging from $19.99 to $7.61, […]

US Post News | January 19, 2023

Read More 'BCRX' Stories Here

BCRX Price Returns

1-mo -5.28%
3-mo -24.64%
6-mo -2.40%
1-year -28.85%
3-year 261.09%
5-year 130.00%
YTD -7.84%
2022 -17.11%
2021 85.91%
2020 115.94%
2019 -57.25%
2018 64.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7041 seconds.